Manufacturer
INTAS PHARM LTD
Contents
Irinotecan HCl trihydrate
Indication
In combination w/ 5-fluorouracil (5-FU) & folinic acid for advanced colorectal cancer in patient w/o prior chemotherapy for advanced disease or as a single agent in patients who have failed an established 5-FU containing treatment regimen.
Instruction
Strictly follow the recommended dosage unless directed otherwise by the physician. All doses of irinotecan should be administered as an intravenous infusion over 30 to 90 minutes.
Drug interaction
Increased systemic exposure w/ CYP3A4 &/or UGT1A1 inhibitors. Increased exposure to SN-38 w/ ketoconazole & atazanavir sulfate. Reduced exposure to SN-38 w/ CYP3A-inducing anticonvulsant drugs eg, carbamazepine, phenobarb or phenytoin & St. John's wort. Prolonged neuromuscular blocking effects. Exacerbated adverse effects w/ antineoplastic agents. Enhanced lymphocytopenia w/ dexamethasone. Worsened diarrhea incidence or severity w/ laxatives. Dehydration w/ diuretics.
Malaysia
